Gregory Hamilton - Epigenomics AG Insider

Epigenomics AG -- USA Stock  

USD 5.65  0.00  0.00%

CEO

Mr. Gregory Hamilton is Chief Executive Officer at Epigenomics AG since July 1, 2016. He has over 20 years of management experience in molecular diagnostics, manufacturing and professional service industries. Prior to joining Epigenomics, Mr. Hamilton was Chief Executive Officer Director of AltheaDx Inc., Chief Operating Officer and Chief Financial Officer of Enigma Diagnostics Inc., Vice President of Operations and Finance at Third Wave Technologies Inc. and Vice President of Operations at Hologic Inc. He was responsible for multiple FDAcleared products including a Human Papilloma Virus High Risk Screening assay and the first ever cleared HPV genotyping assay
Age: 45  CEO Since 2016  MBA    
49 30 243 450  http://www.epigenomics.com
Hamilton received his MBA from the University of Chicago and his BS in Finance from Purdue University.

Management Efficiency

The company has return on total asset (ROA) of (44.29) % which means that it has lost $44.29 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (122.69) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 607.04 K in total debt with debt to equity ratio (D/E) of 5.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Epigenomics AG has Current Ratio of 1.92 which is within standard range for the sector.

Similar Executives

Entity Summary

Epigenomics AG, a molecular diagnostics company, focuses on developing and commercializing in vitro diagnostic tests for the screening, early detection, and diagnosis of cancer in Germany and internationally. Epigenomics AG (EPGNF) is traded on OTC Market in USA. It is located in Berlin, and employs 43 people.

Did you try this?

Run Global Markets Map Now
   

Global Markets Map

Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Hide  View All  Next  Launch Global Markets Map
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Epigenomics AG to your portfolio

Top Management

Epigenomics AG Leadership Team
Albert Weber, SVP
Antje Zeise, Executive
Guenther Reiter, Executive
Gregory Hamilton, CEO, MBA
Ann Kessler, Executive
Heino Prondzynski, Chairman
Thomas Taapken, CEO
Annett Dietrich, Executive
Noel Doheny, CEO
Nicola HennebergBusse, President
Uwe Staub, COO, Ph.D
Peter Vogt, Executive

Stock Performance

Epigenomics AG Performance Indicators
Return On Equity(122.69) %
Return On Asset(44.29) %
Operating Margin(418.57) %
Current Valuation104.35 M
Price to Earning(8.47) times
Price to Book11.08 times
Price to Sales39.6 times
Revenue3.16 M
Gross Profit1000 K
EBITDA(13.22 M)